rehabilitation management of parkinsons disease n.
Skip this Video
Loading SlideShow in 5 Seconds..
Rehabilitation Management of Parkinsons Disease PowerPoint Presentation
Download Presentation
Rehabilitation Management of Parkinsons Disease

Rehabilitation Management of Parkinsons Disease

807 Vues Download Presentation
Télécharger la présentation

Rehabilitation Management of Parkinsons Disease

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Rehabilitation Management of Parkinsons Disease Susan Stickevers, MD Residency Program Director & Assistant Clinical Professor, SUNY Stony Brook Dept of PM&R

  2. Parkinsons Disease • Is a chronic, progressive neurodegenerative disorder with a multifactorial etiology. • It is superseded only by Alzheimer’s Disease as the most common neurodegenerative disorder

  3. Demographics of Parkinsons Disease • Prevalence of 0.3 % in the US population • 1 – 2% of all persons > 65 yrs old • 4 – 5% of all persons > 85 yrs old • In US : > 1 million have diagnosis of Parkinsons – this is greater than the combined number of MS, ALS, and muscular dystrophy patients added together • Usual age at onset – early 60s • 10% of all those affected are < 45 yrs old – referred to as young onset Parkinsons • 40, 000 new cases of PD will diagnosed this year • Lifetime risk of Parkinsons for men : 2.0% • Lifetime risk for women : 1.3% • Incidence of the disease is lower in African Americans than in Caucasians in the USA

  4. An Interesting Fact • The Chinese have the lowest rates of Parkinsons Disease • It has been suggested by Fahn & Jankovic that this is may be due to consumption of large amounts of green tea by the Chinese which contains antioxidants

  5. Etiology • Parkinsonian symptoms can arise from either the neuropathological condition PD (idiopathic PD) or other forms of Parkinsonism • For neuropathological PD, 90% of cases are sporadic • 10% are of genetic origin – 6 different gene mutations have been identified – the Parkin genes • Genetic forms of PD are seen more frequently in young onset PD • A combination of environmental factors or toxins, genetic susceptibility, and the aging process may account for many of the sporadic cases

  6. Secondary Parkinsons • Can be caused by : • Medications – antipsychotics & antiemetics, lithium, reserpine, aldomet • Sequelae of CNS infection – Prion Diseases, Jakob Creuzfeldt, SSPE, HIV, post encephalitic • Toxin Exposure – Manganese, Rotenone, Paraquat • Vascular Metabolic Disorders – Binswanger’s Disease • Drug Induced – MPTP – byproduct of Ecstasy production • Certain neurodegenerative conditions may exhibit also exhibit Parkinsonian features, these are called the Parkinsons Plus Syndromes – included in this category are progressive supranuclear palsy, MSA, Lewy Body Dementia and CBD • Trauma – Pugilistic encephalopathy

  7. Risk Factors for Parkinsons Disease • The most important risk factor for Parkinsons is advancing age. • Other environmental or lifestyle risk factors associated with Parkinsons include : • Rural living • Exposure to herbicides & pesticides – exposure to the synthetic pesticide paraquat is associated with Parkinsons (organic pesticides are not necessarily safe - rotenone or Derris Dust exposure can induce Parkinsonism) • Drinking well water • Working with solvents – in particular – hexane • Manganese toxicity – sometimes seen in welders, or patients exposed to incorrectly prepared TPN solutions

  8. Idiopathic Parkinsonism • Most common form of Parkinsonism : • Idiopathic form first described by James Parkinson, A British surgeon & paleontologist in 1817 in his “Essay on the Shaking Palsy”

  9. Pathophysiology of Idiopathic Parkinsons • Pathological hallmark of PD : degeneration of dopaminergic neurons in the substantia nigra compacta, resulting in depletion of striatal dopamine • This neurotransmitter regulates excitatory & inhibitory outflow from the basal ganglia • Some of the dopaminergic neurons survive, and these are found to contain Lewy Bodies

  10. Pathophysiology of Parkinsons • Lewy Bodies are eosinophilic intracytoplasmic inclusions, composed of numerous proteins • Protein accumulation plays a prominent role in the pathogenesis of both sporadic & familial forms of PD • Lewy bodies may actually be cytoprotective

  11. Lewy Bodies • The neurodegenerative process in PD is not limited to the substantia nigra compacta • Neuronal loss also happens in other brain regions, which accounts for the motor & non motor features of the disease

  12. Parkinsons Disease – The Six Cardinal Features • Tremor at rest • Rigidity • Bradykinesia • Loss of postural reflexes • Flexed Posture • Freezing (Motor Block) • Diagnostic Criteria : Definite Parkinsons : at least two of these features must be present, one of them being # 1 or # 2 • Probable : Feature # 1 or feature # 2 is present • Possible : at least two of features # 3 – 6 must be present

  13. Diagnostic Testing • There are no clinical tests widely available to definitively make the diagnosis, however, if confirmation of the clinical diagnosis is desired, order serial 6 – fluoro L dopa PET scans which will demonstrate a gradual decline in uptake in the putamen & caudate in the Parkinsons patient • Alternative Imaging Study - Serial Beta CIT SPECT imaging revealing gradual loss of function in the striatum • On the right, see the PET scan of a patient who underwent implantation of fetal tissue into the right putamen - note the recovery of function in the right putamen and the progressive loss of function in the left putamen

  14. Typical MRI Appearance in Parkinsons Disease • Standard MRI studies in Parkinsons are normal • If warranted, consider High Field Strength 1.5 Tesla T2 weighted Brain MRI • Typical Appearance in Parkinsons : wider area of lucency will be noted in the subthalamic nucleus that is probably indicative of increased accumulation of iron – iron deposition occurs when there is a loss of connectivity to the cortex

  15. Early Non - Specific Signs of Parkinsons • Generalized stiffness • Pain or Paresthesias of the limbs – in particular, shoulder pain • Constipation • Low Uric Acid Levels • Sleeplessness • Reduction in volume of the voice • Loss of sense of smell • Seborrheic Dermatitis – see photo on the right • These symptoms precede onset of the motor symptoms of Parkinsons • A Retrospective Study of Early Symptoms of Parkinsons Disease, Przuntek, 1992)

  16. Early Signs of Parkinsonism • Problems with fine motor skills • Decreased sense of smell • Loss of appetite • Tremor occurring with anxiety • Decreased arm swing on one side – a principal finding in Parkinsons is asymmetry in neurological findings • Decreased emotional expression • Personality changes, especially introversion & inflexibility

  17. Parkinsonism is Frequently Misdiagnosed • Clinical presentation may vary from patient to patient • It is not uncommon for PD symptoms to go unrecognized or unreported for years

  18. Two Major Forms of Parkinsonism • Tremor Dominant – has a better prognosis • PIGD – Postural Instability & Gait Dysfunction Variant – has a poorer prognosis

  19. The Cardinal Features : Bradykinesia • Bradykinesia manifests itself as : • Slow reaction times • Impaired fine motor coordination that interferes with ADL • Drooling due to failure to swallow saliva • Monotonic & hypophonic dysarthria : due to incoordination of the muscles of vocalization • Loss of facial expression (hypomimia) – leads to mask facies & decreased blink rate • Reduced armswing when walking • Micrographia – small cramped handwriting • Bradyphrenia – slowness of thought • The extreme form ofbradykinesia is akinesia : the inability to initiate movement • Bradykinesia is the most disabling feature of Parkinsonism. • With a sudden surge in emotional energy, the bradykinetic patient may be able to catch a ball or make a fast movement • This phenomenon is called kinesia paradoxica

  20. Pathophysiology of Bradykinesia • Thought to result from failure of basal ganglia output to reinforce the cortical mechanisms that prepare & execute the commands to move • Reduced dopaminergic function disrupts normal motor cortex activity • Secondary factors which contribute to bradykinesia include muscle weakness, tremor, and rigidity • Bradykinesia results from excessive activity in the subthalamic nucleus and the internal segment of the globus pallidus

  21. The Cardinal Symptoms : Tremor • Resting tremor may be considered to be the most typical sign of Parkinsons • A common initial symptom of the disease is an asymmetrical resting tremor – seen in 70 – 90% of patients at presentation • Asymmetrical resting tremor usually involves the thumb or wrist • If resting tremor is not present, consider that the patient’s Parkinsonian symptoms are caused by a disorder other than PD • The typical resting tremor has a frequency between 4 – 6 Hz • Tremor is most prominent in the distal part of an extremity – in the hand, called a pill rolling tremor • Pill rolling tremor involves the forefinger & thumb at a frequency of 3 -6 cycles per second is the classical presentation of tremor • When tremor is present in the head, it occurs in the region of the lips, chin and jaw – only occasionally in the neck • **Tremor is more likely to be the presenting symptom in young patients, whereas older patients have more prominent bradykinesia**

  22. Treatment of Tremor • Anticholinergics are effective in treatment of resting tremor • Usually used in younger patients ( < 60 yrs) with intact cognition & predominant tremor • Benztropine • Trihexyphenidyl • Side Effects : constipation, blurry vision, urinary retention, confusion, hallucinations

  23. Prognostic Significance of Tremor • Presentation with tremor as the initial symptom often confers a positive prognosis – slower progression • There is a subset of patients with Parkinsons who have “benign tremulous parkinsonism” – these patients have : • A family history of tremor • Minimal progression of the disease process • Poor response to levodopa

  24. Rigidity & Flexed Posture • Rigidity is manifested by increased resistance throughout the range of motion • Rigidity can manifest itself proximally – in the neck, shoulders, and hips • Gait in Parkinsons is characterized as : • Short & shuffling steps • Stooped posture • Narrow base of support • Flexed knees

  25. The Cardinal Signs : Flexed Posture - Camptocormia • Patient on the left had camptocormia due to unrecognized, untreated Parkinsonism • The picture on the right depicts his response to a single test dose of Sinemet. • Camptocormia is a postural deformity seen in the Parkinsons patient • This manifestation of Parkinsonism is often dismissed by physicians as hysteria

  26. The Cardinal Signs – Freezing • Freezing is also known as motor block • Most often affects the legs when walking, but it can also affect the arms and eyelids • Freezing consists of a sudden, transient inability to move • It typically causes hesitation when initiating walking & sudden inability to move feet when turning or walking thru narrow passages – such as doors or elevators – or when patients are about to reach a target destination • Freezing is thought to related to noradrenergic deficiency related to degeneration of the locus coeruleus

  27. The Use of Gestes Antagonistes to Overcome Freezing • Patients learn (or may be taught) a variety of tricks (French : gestes antagonistes) to overcome freezing attacks, such as : • Marching to command (left, right,left, right) • Stepping over objects, such as a crack in the pavement, the end of a walking stick • Walking to music or a metronome • Shifting body weight • Rocking movements trunk • Train your patient to perform gestes antagonistes !!!

  28. Association of Freezing with the Parkinsons Plus Syndromes • When freezing occurs early in the disease process, (< 3 yrs.) or early postural instability (< 3yrs) is present, or is a predominant symptom : • Consider that your patient may have a Parkinsons Plus Syndrome – not Parkinsons - such as • PSP • MSA • Vascular Parkinsons

  29. Non Motor Features of Parkinsons • The clinical course of Parkinsons is not limited to motor symptoms • Non motor symptoms & disorders significantly affect the health related quality of life (HRQOL) • Surveys of PD patients reveal that approximately 90% have at least 1 non motor symptom • 10% of PD patient have 5 non motor symptoms • The non motor symptoms contribute to shortened life expectancy

  30. Common Non - Motor Features of Parkinsons • Neuropsychiatric • Impulse Control Disorders • Sleep Disorders • Autonomic Dysfunction – orthostatic hypotension, hyperhidrosis, hypohidrosis, sexual impotence can be seen in Parkinsons – but if these features are noted early in disease process, your patient may have MSA • Sensory Symptoms – paresthesias, oral & genital pain are common – as is olfactory dysfunction • Other – Fatigue, Seborrhea, Diplopia, Blurred Vision, Weight Loss

  31. Neuropsychiatric Disorders in Parkinsons Disease • Depression • Anxiety, including panic attacks • Cognitive Dysfunction • Dementia • Psychosis • Confusion or delirium • Apathy

  32. Depression in Parkinsons • Most common neuropsychiatric disorder in PD patients, affecting up to 50% • Depression is often comorbid with anxiety disorder • Can be observed at any stage of the illness – including prior to onset of motor symptoms • Depression is associated with increased disability, poor HRQOL, and a more rapid progression of motor impairment • It is unclear whether or not the depression is reactive or related to neuropathology • Most patients with Parkinsons who are depressed are not treated or treated inadequately for depression – resulting in increased disability • Weintraub et al, J. of Geriatric Psychiatry & Neurology, 2003 • Routine screening for depression & anxiety with a validated instrument is recommended • Validated Instruments : Beck Depression Inventory, Geriatric Depression Screen, Hamilton Depression Inventory, Beck Anxiety Inventory, Speilberger State Trait Anxiety Inventory

  33. Risk Factors for Depression in the Parkinsonian Patient • Increasing severity of cognitive impairment • Female gender • Early onset disease • Personal history of depression prior to onset of disease

  34. Treatment of Depression – Evidence Based Medicine • Meta – Analysis : Fewer than 30 studies exist in the literature which evaluate the effectiveness of antidepressants in PD • The AAN recommends the use of amitriptyline for the treatment of depression in PD based on their review of available studies • TCAs may not be well tolerated by all Parkinsons patients due to the side effect profile – particularly the orthostasis & worsening cognition

  35. Most Frequently Used Antidepressants in Parkinsons • SSRIs are the most commonly used antidepressants • Well tolerated by the major of patients • This class of drugs do not appear to worsen motor symptoms in PD • In open label clinical trials, most PD patients did not experience side effects with maximal dosages • **Citalopram, escitalopram, and sertraline are recommended** - less prone to drug – drug interactions than paroxetine or fluoxetine

  36. Antidepressant Doses

  37. Anxiety in Parkinson Patients • Avoid benzodiazepines as these increase the risk to fall • Consider the use of an antidepressant which is also effective against anxiety • Escitalopram is a good choice of an antidepressant which can also act as an anxiolytic • Buspirone is well tolerated but has not been formally tested for its effectiveness in PD patients

  38. Cognitive Dysfunction & Dementia in PD • Prevalence of dementia : 20 – 40% of PD patients : Six times higher than in the general population • Characterized by : • Psychomotor slowing • Impaired executive function • Inattention • Impaired visuospatial abilities • Memory impairment – due to poor retrieval of information in PD – as opposed to poor encoding of new information seen in Alzheimers Disease • Verbal cueing may aide recall in Parkinsons patients – this is not usually helpful in Alzheimers

  39. Neurobiology of Development of Dementia in PD • Neurotransmitter deficits are responsible : • Decreased levels of the following are observed in PD : • Acetylcholine • Dopamine • Serotonin • Norepinephrine • Cholinergic & dopaminergic deficits have been linked to memory dysfunction & dysexecutive syndrome • Noradrenergic deficits have been linked to inattention • **Consider neuropsychological testing on all your PD patients at regular intervals**

  40. Recommended Screening Tools for Dementia in the Parkinsons Patient • Cambridge Cognitive Examination • Folstein Mini Mental Status Exam • Montreal Cognitive Assessment – highly effective in detecting early cognitive changes • Hopkins Verbal Learning Test – assesses verbal memory abilities & recognition recall • Clock Drawing Test – useful to asses visuospatial & executive abilities

  41. Comparison of the Clinical Features of Lewy Body Dementia, Parkinsons Dementia, & Alzheimers Disease

  42. Risk Factors for Development of Dementia in Parkinsons Patients • Old age • Older age at onset • Increased severity of PD • Depression • Psychosis • Early executive impairment • Early memory deficits

  43. Is it Lewy Body Dementia or Parkinsons? • The presence of dementia & psychosis early in the disease course is highly uncharacteristic of PD and favors a diagnosis of Lewy Body dementia

  44. Treatment of Dementia in Parkinsons • Rivastigmine (Exelon) was found to be moderately effective in Parkinsons dementia in a large placebo controlled study & has received FDA approval for this indication • In small studies, the anticholinesterase donepezil in PD patients with dementia • Very rarely do these medications cause a worsening of Parkinsonian symptoms

  45. Drugs for Cognitive Dysfunction in Parkinsons Disease

  46. Impulse Control Disorders (ICD) • Impulse control disorders are defined as failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or others • Manifestations include compulsive gambling, hypersexuality, shopping, and binge eating. • ICD occurs at a frequency of 1.5% of the general population • In Parkinson Disease, one large scale study suggests that ICD affects 10 – 15% of patients with PD

  47. Etiology of ICD in Parkinsons • Primary Etiology of ICD in Parkinsons – dopamine agonist therapy • No one agent has been identified to be more likely than another to induce ICD • Higher doses predict a greater risk for ICD • A history of ICD before onset of Parkinsons is a risk factor for exacerbation of this syndrome after initiation of dopamine agonist therapy • When prescribing dopaminergic agonist therapy, patients must be warned about the potential for developing an ICD • Screen patients on dopaminergic agonists for an ICD with the Minnesota Impulse Disorders Interview

  48. Treatment of ICDs in Parkinsons • When ICDs develop in the Parkinsons patient, consider : • Dose reduction • Discontinuing dopaminergic agonist • Switching to another dopaminergic agonist • Consider a trial of an SSRI • Consider a trial of an atypical antipsychotic

  49. Sleep Disturbance in Parkinsons • Some patients remain awake 30 – 40% of the night • Sleep dysfunction is manifested as : • Parasomnias • Nocturnal Insomnia • Difficulty initiating or maintaining sleep • Daytime Hypersomnolence

  50. Etiologies of Sleep Disturbance in Parkinsons • Nocturia • “Wearing off” motor disability • Sleep Apnea – due to rigidity in phargyneal & respiratory musculature & neuropathological changes • Periodic Leg Movements • Restless Leg Syndrome – occurs in 20% of Parkinsons patients • Depression / Anxiety • Neuropathological Changes – degeneration of the brainstem nuclei involved in respiration • Medication related – for example, selegiline has amphetamine derative metabolites